Top

Published in:

Open Access 01-12-2023 | Cholangitis | Research

Elevated plasma and bile levels of corisin, a microbiota-derived proapoptotic peptide, in patients with severe acute cholangitis

Authors: Ryo Nishiwaki, Ichiro Imoto, Satoko Oka, Taro Yasuma, Hajime Fujimoto, Corina N. D’Alessandro-Gabazza, Masaaki Toda, Tetsu Kobayashi, Hataji Osamu, Kodai Fujibe, Kenichiro Nishikawa, Tetsuya Hamaguchi, Natsuko Sugimasa, Midori Noji, Yoshiyuki Ito, Kenji Takeuchi, Isaac Cann, Yasuhiro Inoue, Toshio Kato, Esteban C. Gabazza

Published in: Gut Pathogens | Issue 1/2023

Abstract

Background

Acute cholangitis is a severe, life-threatening infection of the biliary system that requires early diagnosis and treatment. The Tokyo Guidelines recommend a combination of clinical, laboratory, and imaging findings for diagnosis and severity assessment, but there are still challenges in identifying severe cases that need immediate intervention. The microbiota and its derived products have been implicated in the pathogenesis of acute cholangitis. Corisin is a microbiome-derived peptide that induces cell apoptosis, acute tissue injury, and inflammation. This study aimed to evaluate the potential of plasma and bile corisin as a biomarker of acute cholangitis.

Methods

Forty patients with acute cholangitis associated with choledocholithiasis or malignant disease were enrolled. Nine patients without acute cholangitis were used as controls. Corisin was measured by enzyme immunoassays in plasma and bile samples. Patients were classified into severe and non-severe groups. The associations of plasma and bile corisin with the clinical grade of acute cholangitis and other parameters were analyzed by univariate and multivariate regression analysis.

Results

Plasma and bile corisin levels were significantly higher in patients with acute cholangitis than in controls. Patients with severe acute cholangitis had significantly higher plasma and bile corisin levels than those with non-severe form of the disease. Bile corisin level was significantly correlated with markers of inflammation, coagulation, fibrinolysis, and renal function. Univariate analysis revealed a significant association of bile corisin but a weak association of plasma corisin with the clinical grade of acute cholangitis. In contrast, multivariate analysis showed a significant relationship between plasma corisin level and the disease clinical grade. The receiver operating characteristic curve analysis showed low sensitivity but high specificity for plasma and bile corisin to detect the severity of acute cholangitis. The plasma and bile corisin sensitivity was increased when serum C-reactive protein level was included in the receiver operating characteristic curve analysis.

Conclusions

Overall, these findings suggest that plasma and bile corisin levels may be useful biomarkers for diagnosing and monitoring acute cholangitis and that corisin may play a role in the pathophysiology of the disease by modulating inflammatory, coagulation and renal pathways.

Available only for authorised users

Ahmed M. Acute cholangitis: an update. World J Gastrointest Pathophysiol. 2018;9(1):1–7. https://doi.org/10.4291/wjgp.v9.i1.1.CrossRefPubMedPubMedCentral

Gomi H, Takada T, Hwang TL, Akazawa K, Mori R, Endo I, et al. Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis. J Hepatobiliary Pancreat Sci. 2017;24(6):310–8. https://doi.org/10.1002/jhbp.452.CrossRefPubMed

Mohammad Alizadeh AH. Cholangitis diagnosis, treatment and prognosis. J Clin Transl Hepatol. 2017;5(4):404–13. https://doi.org/10.14218/JCTH.2017.00028.CrossRefPubMedPubMedCentral

Kimura Y, Takada T, Strasberg SM, Pitt HA, Gouma DJ, Garden OJ, et al. TG13 current terminology, etiology, and epidemiology of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013;20(1):8–23. https://doi.org/10.1007/s00534-012-0564-0.CrossRefPubMed

Kasparian K, Christou CD, Petidis K, Doumas M, Giouleme O. Short vs long-course antibiotic therapy in adults with acute cholangitis: a systematic review, meta-analysis, and evidence quality assessment. World J Gastroenterol. 2023;29(19):3027–39. https://doi.org/10.3748/wjg.v29.i19.3027.CrossRefPubMedPubMedCentral

Kiriyama S, Kozaka K, Takada T, Strasberg SM, Pitt HA, Gabata T, et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25(1):17–30. https://doi.org/10.1002/jhbp.512.CrossRefPubMed

Khashab MA, Tariq A, Tariq U, Kim K, Ponor L, Lennon AM, et al. Delayed and unsuccessful endoscopic retrograde cholangiopancreatography are associated with worse outcomes in patients with acute cholangitis. Clin Gastroenterol Hepatol. 2012;10(10):1157–61. https://doi.org/10.1016/j.cgh.2012.03.029.CrossRefPubMed

Karvellas CJ, Abraldes JG, Zepeda-Gomez S, Moffat DC, Mirzanejad Y, Vazquez-Grande G, et al. The impact of delayed biliary decompression and anti-microbial therapy in 260 patients with cholangitis-associated septic shock. Aliment Pharmacol Ther. 2016;44(7):755–66. https://doi.org/10.1111/apt.13764.CrossRefPubMed

Al-Yahri O, Al-Zoubi RM, Elhuda AA, Ahmad A, Al Dhaheri M, Abdelaziem S, et al. Diagnostic inflammation biomarkers for prediction of 30-day mortality rate in acute cholangitis. Int J Surg Protoc. 2022;26(1):14–21. https://doi.org/10.29337/ijsp.170.CrossRefPubMedPubMedCentral

10.

de Vos WM, Tilg H, Van Hul M, Cani PD. Gut microbiome and health: mechanistic insights. Gut. 2022;71(5):1020–32. https://doi.org/10.1136/gutjnl-2021-326789.CrossRefPubMed

11.

Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol. 2021;18(1):4–17. https://doi.org/10.1038/s41423-020-00592-6.CrossRefPubMed

12.

Di Vincenzo F, Nicoletti A, Negri M, Vitale F, Zileri Dal Verme L, Gasbarrini A, et al. Gut microbiota and antibiotic treatments for the main non-oncologic hepato-biliary-pancreatic disorders. Antibiotics (Basel). 2023. https://doi.org/10.3390/antibiotics12061068.CrossRefPubMed

13.

Sokal A, Sauvanet A, Fantin B, de Lastours V. Acute cholangitis: diagnosis and management. J Visc Surg. 2019;156(6):515–25. https://doi.org/10.1016/j.jviscsurg.2019.05.007.CrossRefPubMed

14.

Mukai S, Itoi T, Tsuchiya T, Ishii K, Tanaka R, Tonozuka R, et al. Urgent and emergency endoscopic retrograde cholangiopancreatography for gallstone-induced acute cholangitis and pancreatitis. Dig Endosc. 2023;35(1):47–57. https://doi.org/10.1111/den.14379.CrossRefPubMed

15.

Han J, Wu S, Fan Y, Tian Y, Kong J. Biliary microbiota in choledocholithiasis and correlation with duodenal microbiota. Front Cell Infect Microbiol. 2021;11: 625589. https://doi.org/10.3389/fcimb.2021.625589.CrossRefPubMedPubMedCentral

16.

Chen B, Fu SW, Lu L, Zhao H. A preliminary study of biliary microbiota in patients with bile duct stones or distal cholangiocarcinoma. Biomed Res Int. 2019;2019:1092563. https://doi.org/10.1155/2019/1092563.CrossRefPubMedPubMedCentral

17.

Grigor’eva IN, Romanova TI. Gallstone disease and microbiome. Microorganisms. 2020. https://doi.org/10.3390/microorganisms8060835.CrossRefPubMedPubMedCentral

18.

Hao Z, Tao K, Wu K, Luo Y, Lu Y, Li B, et al. Alterations of gut microbiome and metabolite profiles in choledocholithiasis concurrent with cholangitis. Hepatol Int. 2022;16(2):447–62. https://doi.org/10.1007/s12072-021-10231-5.CrossRefPubMed

19.

Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65(12):2035–44. https://doi.org/10.1136/gutjnl-2016-312729.CrossRefPubMed

20.

Wu T, Zhang Z, Liu B, Hou D, Liang Y, Zhang J, et al. Gut microbiota dysbiosis and bacterial community assembly associated with cholesterol gallstones in large-scale study. BMC Genomics. 2013;14:669. https://doi.org/10.1186/1471-2164-14-669.CrossRefPubMedPubMedCentral

21.

Beltran MA, Beltran AA. Common bile duct pressure in patients with and without cholelithiasis: a case-control study. J Hepatobiliary Pancreat Sci. 2021;28(5):443–9. https://doi.org/10.1002/jhbp.931.CrossRefPubMed

22.

Zhang R, Luo H, Pan Y, Zhao L, Dong J, Liu Z, et al. Rate of duodenal-biliary reflux increases in patients with recurrent common bile duct stones: evidence from barium meal examination. Gastrointest Endosc. 2015;82(4):660–5. https://doi.org/10.1016/j.gie.2015.03.1908.CrossRefPubMed

23.

Csendes A, Kruse A, Funch-Jensen P, Oster MJ, Ornsholt J, Amdrup E. Pressure measurements in the biliary and pancreatic duct systems in controls and in patients with gallstones, previous cholecystectomy, or common bile duct stones. Gastroenterology. 1979;77(6):1203–10.CrossRefPubMed

24.

D’Alessandro-Gabazza CN, Kobayashi T, Yasuma T, Toda M, Kim H, Fujimoto H, et al. A Staphylococcus pro-apoptotic peptide induces acute exacerbation of pulmonary fibrosis. Nat Commun. 2020;11(1):1539. https://doi.org/10.1038/s41467-020-15344-3.CrossRefPubMedPubMedCentral

25.

D’Alessandro-Gabazza CN, Yasuma T, Kobayashi T, Toda M, Abdel-Hamid AM, Fujimoto H, et al. Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis. Nat Commun. 2022;13(1):1558. https://doi.org/10.1038/s41467-022-29064-3.CrossRefPubMedPubMedCentral

26.

Fridman D’Alessandro V, D’Alessandro-Gabazza CN, Yasuma T, Toda M, Takeshita A, Tomaru A, et al. Inhibition of a microbiota-derived peptide ameliorates established acute lung injury. Am J Pathol. 2023;193(6):740–54. https://doi.org/10.1016/j.ajpath.2023.03.003.CrossRefPubMed

27.

Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, et al. Apoptotic cell death in disease-current understanding of the NCCD 2023. Cell Death Differ. 2023;30(5):1097–154. https://doi.org/10.1038/s41418-023-01153-w.CrossRefPubMedPubMedCentral

28.

Kawata K, Kobayashi Y, Gershwin ME, Bowlus CL. The immunophysiology and apoptosis of biliary epithelial cells: primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol. 2012;43(3):230–41. https://doi.org/10.1007/s12016-012-8324-0.CrossRefPubMed

29.

Farooq U, Gondal AB, Franco D, Tarar ZI, Mahmood S. Validation of Tokyo guidelines 2018 for safety and mortality benefit from urgent ERCP in acute cholangitis across different age groups. J Hepatobiliary Pancreat Sci. 2023;30(6):737–44. https://doi.org/10.1002/jhbp.1275.CrossRefPubMed

30.

Hudgi A, Cartelle AL, Ahmed A, Alkaddour A, Palacio C, Vega KJ, et al. Tokyo guidelines (TG18) for acute cholangitis provide improved specificity and accuracy compared to fellow assessment. Cureus. 2022;14(7): e27527. https://doi.org/10.7759/cureus.27527.CrossRefPubMedPubMedCentral

31.

D’Alessandro-Gabazza CN, Mendez-Garcia C, Hataji O, Westergaard S, Watanabe F, Yasuma T, et al. Identification of halophilic microbes in lung fibrotic tissue by oligotyping. Front Microbiol. 2018;9:1892. https://doi.org/10.3389/fmicb.2018.01892.CrossRefPubMedPubMedCentral

32.

Csendes A, Burdiles P, Maluenda F, Diaz JC, Csendes P, Mitru N. Simultaneous bacteriologic assessment of bile from gallbladder and common bile duct in control subjects and patients with gallstones and common duct stones. Arch Surg. 1996;131(4):389–94. https://doi.org/10.1001/archsurg.1996.01430160047008.CrossRefPubMed

33.

Nielsen ML, Justesen T. Anaerobic and aerobic bacteriological studies in biliary tract disease. Scand J Gastroenterol. 1976;11(5):437–46.CrossRefPubMed

34.

Podgorski PB, Przybylkowski A, Nehring P. Bile composition—which components can have clinical significance? A review of the literature. J Gastrointestin Liver Dis. 2023;32(1):110–7. https://doi.org/10.15403/jgld-4634.CrossRefPubMed

35.

Verdier J, Luedde T, Sellge G. Biliary mucosal barrier and microbiome. Viszeralmedizin. 2015;31(3):156–61. https://doi.org/10.1159/000431071.CrossRefPubMedPubMedCentral

36.

Baum H, Bogdanos DP, Vergani D. Antibodies to Clp protease in primary biliary cirrhosis: possible role of a mimicking T-cell epitope. J Hepatol. 2001;34(5):785–7. https://doi.org/10.1016/s0168-8278(01)00059-9.CrossRefPubMed

37.

Maki T. Pathogenesis of calcium bilirubinate gallstone: role of E. coli, beta-glucuronidase and coagulation by inorganic ions, polyelectrolytes and agitation. Ann Surg. 1966;164(1):90–100. https://doi.org/10.1097/00000658-196607000-00010.CrossRefPubMedPubMedCentral

38.

Maurer KJ, Ihrig MM, Rogers AB, Ng V, Bouchard G, Leonard MR, et al. Identification of cholelithogenic enterohepatic helicobacter species and their role in murine cholesterol gallstone formation. Gastroenterology. 2005;128(4):1023–33. https://doi.org/10.1053/j.gastro.2005.01.008.CrossRefPubMed

39.

Terjung B, Sohne J, Lechtenberg B, Gottwein J, Muennich M, Herzog V, et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut. 2010;59(6):808–16. https://doi.org/10.1136/gut.2008.157818.CrossRefPubMed

40.

Liu J, Yan Q, Luo F, Shang D, Wu D, Zhang H, et al. Acute cholecystitis associated with infection of Enterobacteriaceae from gut microbiota. Clin Microbiol Infect. 2015;21(9):851 e1-9. https://doi.org/10.1016/j.cmi.2015.05.017.CrossRefPubMed

41.

Brun P, Castagliuolo I, Pinzani M, Palu G, Martines D. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2005;289(3):G571–8. https://doi.org/10.1152/ajpgi.00537.2004.CrossRefPubMed

42.

Chen Y, Weng Z, Liu Q, Shao W, Guo W, Chen C, et al. FMO3 and its metabolite TMAO contribute to the formation of gallstones. Biochim Biophys Acta Mol Basis Dis. 2019;1865(10):2576–85. https://doi.org/10.1016/j.bbadis.2019.06.016.CrossRefPubMed

43.

Rahman S, O’Connor AL, Becker SL, Patel RK, Martindale RG, Tsikitis VL. Gut microbial metabolites and its impact on human health. Ann Gastroenterol. 2023;36(4):360–8. https://doi.org/10.20524/aog.2023.0809.CrossRefPubMedPubMedCentral

44.

Sasatomi K, Noguchi K, Sakisaka S, Sata M, Tanikawa K. Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol. 1998;29(3):409–16. https://doi.org/10.1016/s0168-8278(98)80058-5.CrossRefPubMed

45.

Tsuneyama K, Harada K, Kono N, Hiramatsu K, Zen Y, Sudo Y, et al. Scavenger cells with gram-positive bacterial lipoteichoic acid infiltrate around the damaged interlobular bile ducts of primary biliary cirrhosis. J Hepatol. 2001;35(2):156–63. https://doi.org/10.1016/s0168-8278(01)00084-8.CrossRefPubMed

46.

Saiki H, Okano Y, Yasuma T, Toda M, Takeshita A, Abdel-Hamid AM, et al. A microbiome-derived peptide induces apoptosis of cells from different tissues. Cells. 2021. https://doi.org/10.3390/cells10112885.CrossRefPubMedPubMedCentral

47.

Fridgeirsson HF, Konradsson M, Vesteinsdottir E, Bjornsson ES. Incidence and outcomes in patients with acute cholangitis: a population-based study. Scand J Gastroenterol. 2023. https://doi.org/10.1080/00365521.2023.2231585.CrossRefPubMed

48.

Suh SW, Choi YS, Choi SH, Do JH, Oh HC, Kim HJ, et al. Antibiotic selection based on microbiology and resistance profiles of bile from gallbladder of patients with acute cholecystitis. Sci Rep. 2021;11(1):2969. https://doi.org/10.1038/s41598-021-82603-8.CrossRefPubMedPubMedCentral

49.

Lee YS, Cho KB, Park KS, Lee JY, Lee YJ. Procalcitonin as a decision-supporting marker of urgent biliary decompression in acute cholangitis. Dig Dis Sci. 2018;63(9):2474–9. https://doi.org/10.1007/s10620-018-4963-1.CrossRefPubMed

50.

Shinya S, Sasaki T, Yamashita Y, Kato D, Yamashita K, Nakashima R, et al. Procalcitonin as a useful biomarker for determining the need to perform emergency biliary drainage in cases of acute cholangitis. J Hepatobiliary Pancreat Sci. 2014;21(10):777–85. https://doi.org/10.1002/jhbp.132.CrossRefPubMed

51.

Silangcruz K, Nishimura Y, Czech T, Kimura N, Yess J. Procalcitonin to predict severity of acute cholangitis and need for urgent biliary decompression: systematic scoping review. J Clin Med. 2022. https://doi.org/10.3390/jcm11051155.CrossRefPubMedPubMedCentral

52.

Suwa Y, Matsuyama R, Goto K, Kadokura T, Sato M, Mori R, et al. IL-7 and procalcitonin are useful biomarkers in the comprehensive evaluation of the severity of acute cholangitis. J Hepatobiliary Pancreat Sci. 2017;24(2):81–8. https://doi.org/10.1002/jhbp.420.CrossRefPubMed

53.

Umefune G, Kogure H, Hamada T, Isayama H, Ishigaki K, Takagi K, et al. Procalcitonin is a useful biomarker to predict severe acute cholangitis: a single-center prospective study. J Gastroenterol. 2017;52(6):734–45. https://doi.org/10.1007/s00535-016-1278-x.CrossRefPubMed

54.

Deng X, Wang JW, Wu Q, Pan L, Mou T, Du CY. Lipocalin2 as a useful biomarker for risk stratification in patients with acute cholangitis: a single-center prospective and observational study. Clin Chim Acta. 2022;533:22–30. https://doi.org/10.1016/j.cca.2022.05.022.CrossRefPubMed

55.

Oura H, Nishino T, Murakami D, Shima Y, Shirato M, Sugiyama H, et al. Diagnostic value of the serum lactate level as a predictor of bacteremia in patients with acute cholangitis. J Hepatobiliary Pancreat Sci. 2023. https://doi.org/10.1002/jhbp.1343.CrossRefPubMed

56.

Tsuchida T, Ie K, Okuse C, Hirose M, Nishisako H, Torikai K, et al. Determining the factors affecting serum presepsin level and its diagnostic utility: A cross-sectional study. J Infect Chemother. 2021;27(4):585–91. https://doi.org/10.1016/j.jiac.2020.11.013.CrossRefPubMed

Title: Elevated plasma and bile levels of corisin, a microbiota-derived proapoptotic peptide, in patients with severe acute cholangitis
Authors: Ryo Nishiwaki
Ichiro Imoto
Satoko Oka
Taro Yasuma
Hajime Fujimoto
Corina N. D’Alessandro-Gabazza
Masaaki Toda
Tetsu Kobayashi
Hataji Osamu
Kodai Fujibe
Kenichiro Nishikawa
Tetsuya Hamaguchi
Natsuko Sugimasa
Midori Noji
Yoshiyuki Ito
Kenji Takeuchi
Isaac Cann
Yasuhiro Inoue
Toshio Kato
Esteban C. Gabazza
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Cholangitis
Respiratory Microbiota
Choledocholithiasis
Published in: Gut Pathogens / Issue 1/2023
Electronic ISSN: 1757-4749
DOI: https://doi.org/10.1186/s13099-023-00587-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Intravenous antibiotics in preterm infants have a negative effect upon microbiome development throughout preterm life

Retraction Note to: EV71 virus reduces Nrf2 activation to promote production of reactive oxygen species in infected cells

Microbiota promotes recruitment and pro-inflammatory response of caecal macrophages during E. tenella infection

CMTM3 protects the gastric epithelial cells from apoptosis and promotes IL-8 by stabilizing NEMO during Helicobacter pylori infection

Therapeutic and prophylactic effects of oral administration of probiotic Enterococcus faecium Smr18 in Salmonella enterica-infected mice

Severe asthma patient with secondary Citrobacter koseri abdominal infection: first case report and review of the literature

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials